Breaking News

Algorithme Pharma, HMR in Patient Access Pact

By Kristin Brooks | December 11, 2013

To offer patient access in key therapeutic areas

Algorithme Pharma has partnered with Hôpital Maisonneuve-Rosemont (HMR) to offer sponsors increased patient access in key therapeutic areas, including hematology, oncology, nephrology, ophthalmology and metabolic diseases. The HMR clinical research team has more than 60 clinicians and is supported by approximately 75 employees. 
“As sponsors look to obtain more information on their lead drug earlier in development, the need to include patient populations in early stage clinical trials continues to increase. Partnering with research teams who have expertise in key therapeutic areas advances our goal of providing a full spectrum of Phase I/IIa clinical research services to our diverse client base,” said Dr. Marc Lefebvre, vice president Scientific & Regulatory Affairs, Algorithme Pharma.
Dr. Pierre Dubé, associate director, Clinical Research Division, Hôpital Maisonneuve-Rosemont, added, “In this partnership between private and academic organizations, our clinical investigators and researchers will be able to leverage Algorithme Pharma’s immense wealth of knowledge. For HMR and its Research Centre, this kind of collaboration is part of our strategic objectives which aim to continually deliver innovative treatments to our patients.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016